Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Idiopathic Pulmonary Fibrosis
NCT04312594Phase 2Completed
- Sponsor
- Zelgen
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of jaktinib in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Zelgen. Primary endpoint: Changes in forced vital capacity at 24 weeks. Started Sep 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04312594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312594.